Exclusive:Sensory Integration and Its Brain Mechanisms

Cognitive impairment in Parkinson's disease

  • YE Zheng
Expand
  • 1. Key Laboratory of Mental Health, Institute of Psychology;Chinese Academy of Sciences, Beijing 100101, China;
    2. Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai 200031, China;
    3. Department of Psychology, University of Chinese Academy of Sciences, Beijing 100049, China

Received date: 2017-08-15

  Revised date: 2017-08-24

  Online published: 2017-10-18

Abstract

Parkinson's disease is the second most common neurodegenerative disorder following Alzheimer's disease. As the world's population aging grows at an unprecedented rate, so does the population with Parkinson's disease. Cognitive impairment and other nonmotor symptoms have become a major factor in decline of quality of life in Parkinson's patients. However, the biological mechanisms responsible for cognitive impairment in Parkinson's disease have not been identified with certainty. Cognitive impairment is common in Parkinson's patients but often not recognized in clinical practice. Efficacious therapies have to be developed for treating cognitive impairment in Parkinson's disease. This article is to review recent advances in neuroscience and medicine, from the neurochemical basis, genetic risk, and impact of other non-motor symptoms to biomarkers of Parkinson's cognitive impairment.

Cite this article

YE Zheng . Cognitive impairment in Parkinson's disease[J]. Science & Technology Review, 2017 , 35(19) : 49 -55 . DOI: 10.3981/j.issn.1000-7857.2017.19.006

References

[1] Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for de-mentia associated with Parkinson's disease[J]. Movement Disorders, 2007, 22(12):1689-1707.
[2] Litvan I, Goldman J G, Tröster A I, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease:Movement disorder society task force guidelines[J]. Movement Disorders, 2012, 27(3):349-356.
[3] Copeland J N, Lieberman A, Oravivattanakul S, et al. Accuracy of pa-tient and care partner identification of cognitive impairments in Parkin-son's disease-mild cognitive impairment[J]. Movement Disorders, 2016, 31(5):693-698.
[4] Williams-Gray C H, Mason S L, Evans J R, et al. The campaign study of Parkinson's disease:10-year outlook in an incident populationbased cohort[J]. Journal of Neurology, Neurosurgery, and Psychiatry, 2013, 84(11):1258-1264.
[5] Hely M A, Reid W G, Adena M A, et al. The sydney multicenter study of Parkinson's disease:The inevitability of dementia at 20 years[J]. Movement Disorders, 2008, 23(6):837-844.
[6] Pigott K, Rick J, Xie S X, et al. Longitudinal study of normal cognition in Parkinson disease[J]. Neurology, 2015, 85(15):1276-1282.
[7] Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update:Treatments for the non-motor symptoms of Parkinson's disease[J]. Movement Disorders, 2011, 26(Sup-pl 3):S42-80.
[8] Goldman J G, Weintraub D. Advances in the treatment of cognitive im-pairment in Parkinson's disease[J]. Movement Disorders, 2015, 30(11):1471-1489.
[9] Parsons T D, Rogers S A, Braaten A J, et al. Cognitive sequelae of sub-thalamic nucleus deep brain stimulation in Parkinson's disease:A me-ta-analysis[J]. Lancet Neurology, 2006, 5(7):578-588.
[10] Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease:A ran-domised, multicentre study[J]. Lancet Neurology, 2008, 7(7):605-614.
[11] Alomar S, King N K, Tam J, et al. Speech and language adverse ef-fects after thalamotomy and deep brain stimulation in patients with movement disorders:A meta-analysis[J]. Movement Disorders, 2017, 32(1):53-63.
[12] Daniels C, Krack P, Volkmann J, et al. Risk factors for executive dys-function after subthalamic nucleus stimulation in Parkinson's disease[J]. Movement Disorders, 2010, 25(11):1583-1589.
[13] Leung I H, Walton C C, Hallock H, et al. Cognitive training in Parkin-son disease:A systematic review and meta-analysis[J]. Neurology, 2015, 85(21):1843-1851.
[14] Costa A, Peppe A, Dell'Agnello G, et al. Dopamine and cognitive func-tioning in de novo subjects with Parkinson's disease:Effects of prami-pexole and pergolide on working memory[J]. Neuropsychologia, 2009, 47(5):1374-1381.
[15] Durstewitz D and Seamans J K The dual-state theory of prefrontal cor-tex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia[J]. Biological Psychiatry, 2008, 64(9):739-749.
[16] Ye Z, Altena E, Nombela C, et al. Selective serotonin reuptake inhibi-tion modulates response inhibition in Parkinson's disease[J]. Brain, 2014, 137(4):1145-55.
[17] Ye Z, Altena E, Nombela C, et al. Improving response inhibition in Parkinson's disease with atomoxetine.[J]. Biological Psychiatry, 2015, 77(8):740-748.
[18] Healy D G, Falchi M, O'Sullivan S S, et al. Phenotype, genotype, and worldwide genetic penetrance of lrrk2-associated Parkinson's disease:A case-control study[J]. Lancet Neurology, 2008, 7(7):583-590.
[19] Wang C, Cai Y, Gu Z, et al. Clinical profiles of Parkinson's disease as-sociated with common leucine-rich repeat kinase 2 and glucocerebro-sidase genetic variants in Chinese individuals[J]. Neurobiology of Ag-ing, 2014, 35(3):725-726.
[20] Thaler A, Mirelman A, Gurevich T, et al. Lower cognitive performance in healthy g2019s lrrk2 mutation carriers[J]. Neurology, 2012, 79(10):1027-1032.
[21] Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease[J]. Brain, 2009, 132(7):1783-1794.
[22] Winder-Rhodes S E, Evans J R, Ban M, et al. Glucocerebrosidase mu-tations influence the natural history of Parkinson's disease in a com-munity-based incident cohort[J]. Brain, 2013, 136(2):392-399.
[23] Zhang Y, Sun Q Y, Zhao Y W, et al. Effect of gba mutations on pheno-type of Parkinson's disease:A study on Chinese population and a me-ta-analysis[J]. Parkinson's Disease, 2015, 2015:916971.
[24] Mata I F, Leverenz J B, Weintraub D, et al. Gba variants are associat-ed with a distinct pattern of cognitive deficits in Parkinson's disease[J]. Movement Disorders, 2016, 31(1):95-102.
[25] Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in gba-asso-ciated Parkinson's disease:The mutation matters[J]. Annals of Neurol-ogy, 2016, 80(5):662-673.
[26] Williams-Gray C H, Evans J R, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease:5 year follow-up of the campaign cohort[J]. Brain, 2009, 132(Pt11):2958-2969.
[27] Nombela C, Rowe J B, Winder-Rhodes S E, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease:Icicle-pd study[J]. Brain, 2014, 137(10):2743-2758.
[28] Mata I F, Leverenz J B, Weintraub D, et al. Apoe, mapt, and snca genes and cognitive performance in Parkinson disease[J]. JAMA Neu-rology, 2014, 71(11):1405-1412.
[29] Federoff M, Jimenez-Rolando B, Nalls M A, et al. A large study re-veals no association between apoe and Parkinson's disease[J]. Neurobi-ology of Disease, 2012, 46(2):389-92.
[30] Kurz M W, Dekomien G, Nilsen O B, et al. Apoe alleles in Parkinson disease and their relationship to cognitive decline:A populationbased, longitudinal study[J]. Journal of Geriatric Psychiatry and Neu-rology, 2009, 22(3):166-170.
[31] Pushpanathan M E, Loftus A M, Thomas M G, et al. The relationship between sleep and cognition in Parkinson's disease:A meta-analysis[J]. Sleep Medicine Reviews, 2016, 26:21-32.
[32] Anang J B, Gagnon J F, Bertrand J A, et al. Predictors of dementia in Parkinson disease:A prospective cohort study.[J]. Neurology, 2014, 83(14):1253-1260.
[33] Domellöf M E, Lundin K F, Edström M, et al. Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease[J]. Parkinsonism & Related Disorders, 2017, Epub ahead of print.
[34] Morley J F, Weintraub D, Mamikonyan E, et al. Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's dis-ease[J]. Movement Disorders, 2011, 26(11):2051-2057.
[35] den Brok M G, van Dalen J W, van Gool W A, et al. Apathy in Par-kinson's disease:A systematic review and meta-analysis[J]. Move-ment Disorders, 2015, 30(6):759-769.
[36] Allcock L M, Kenny R A, Mosimann U P, et al. Orthostatic hypoten-sion in Parkinson's disease:Association with cognitive decline[J]. In-ternational Journal of Geriatric Psychiatry, 2006, 21(8):778-783.
[37] Hohler A D, Zuzuárregui J R, Katz D I, et al. Differences in motor and cognitive function in patients with Parkinson's disease with and without orthostatic hypotension[J]. International Journal of Neurosci-ence, 2012, 122(5):233-236.
[38] Idiaquez J, Benarroch E E, Rosales H, et al. Autonomic and cognitive dysfunction in Parkinson's disease[J]. Clinical Autonomic Research, 2007, 17(2):93-98.
[39] Peralta C, Stampfer-Kountchev M, Karner E, et al. Orthostatic hypo-tension and attention in Parkinson's disease with and without dementia[J]. Journal of Neural Transmission (Vienna), 2007, 114(5):585-588.
[40] Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, et al. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease[J].Movement Disorders, 2016, 31(6):861-881.
[41] Leaver K and Poston K L Do csf biomarkers predict progression to cog-nitive impairment in Parkinson's disease patients? A systematic review[J]. Neuropsychological Review, 2015, 25(4):411-423.
[42] Schrag A, Siddiqui U F, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with new-ly diagnosed Parkinson's disease:A cohort study[J]. Lancet Neurology, 2017, 16(1):66-75.
[43] Ye Z, Rae C L, Nombela C, et al. Predicting beneficial effects of atom-oxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.[J]. Human Brain Mapping, 2016, 37(3):1026-1037.
Outlines

/